Introduction
Malignant transformation results from the accumulation of somatic mutations aecting multiple pathways that control cell growth and dierentiation (Hanahan and Weinberg, 2000) . In most cancers this process takes time as the malignant clone gradually accumulates malignant characteristics via acquired somatic mutations. In some tumor types, however, aberrant transcription factors may functionally substitute for these mutations of pathway constituents (Look, 1995; Rabbitts, 1994) . Of their very nature, such transcription factors may simultaneously aect more than one pathway of oncogenesis, thus accounting for their strong association with some disease types.
The human tumors Ewing's sarcoma (ES) and peripheral primitive neuroectodermal tumor (pPNET) constitute a distinct clinical and pathologic grouping. These EFT are the second most common bone and soft tissue tumor of childhood and adolescence. The tumors typically follow an aggressive clinical course and require aggressive multimodal therapy (Horowitz, 1997) . EFT are united by their extremely high association with aberrant transcription factors fusing the amino terminal portion of the EWS gene with the carboxyl terminus of a member of the ETS transcription factor family (Delattre et al., 1992) . The prototype for these EWS/ets transcription factors is EWS/FLI, seen in over 85% of EFT's. EWS/ets proteins have been shown to act as chimeric transcription factors which presumably act via aberrant regulation of transcriptional targets (May et al., 1993a,b) . Therefore, in order to understand and design therapies for this malignancy it is crucial that we ®rst understand the role played by the various target genes whose expression is modulated by EWS/FLI.
Recently, we have demonstrated that EWS/ets proteins upregulate platelet derived growth factor-C (PDGF-C) in a murine ®broblast transformation model (Zwerner and May, 2001) . PDGF-C is a newly discovered member of a growth factor family that also includes PDGF-A, PDGF-B and PDGF-D (Li et al., 2000) . Like other members of this family, PDGF-C binds to and signals through the platelet derived growth factor receptor alpha and beta subunits (PDGFR-a and PDGFR-b) (Gilbertson et al., 2001) . PDGF-C demonstrates substantial transformation and tumorigenesis potential in this ®broblast model. Furthermore, PDGF-C is expressed in many EFT cell lines and primary tumors. This expression appears to be dependent on EWS/FLI function, since dominant negative blockade of EWS/FLI leads to reduced levels of PDGF-C transcript. Despite these encouraging data, it is unclear to what degree a PDGF-C/PDGFR autocrine loop contributes to the malignant phenotype in more relevant systems such as EFT cell lines. To determine this, it is necessary to disrupt the presumed autocrine loop within EFT tumor cell lines and demonstrate a reversion in cellular transformation.
Here we present evidence that this EWS/ets driven expression of PDGF-C in EFT cell lines produces an autocrine growth loop that is important for neoplastic transformation. We demonstrate that anchorage-independent growth in EFT cell lines can be inhibited by compounds known to selectively block platelet derived growth factor receptor (PDGFR) signaling. We describe a modi®ed form of PDGF-C which has greatly attenuated capacity to activate PDGFR and which blocks PDGF-C transformation in ®broblasts. Finally, we demonstrate that this dominant negative PDGF-C construct eectively inhibits anchorage-independent growth in EFT cell lines. These data support a signi®cant role of PDGF-C in the biology of EFT and implicate it as a possible therapeutic target.
Results

AG1296, a PDGFR-a and b specific inhibitor, inhibits EFT anchorage-independent growth
Certain tumor cell lines have been shown to be stimulated by an autocrine growth factor loop involving PDGF-A (reviewed in Ostman and . Given the relationship between EWS/ets expression and PDGF-C upregulation, we hypothesized that EFT cell lines may harbor a similar autocrine loop involving PDGF-C and its proven receptors, PDGFRa and b. In order to determine the impact of PDGFR-a and b signaling on the growth characteristics of EFT cell lines, we employed pharmacologic blockade of PDGFR signaling. The tryphostin compound AG1296 has been shown to speci®cally inhibit both PDGF-a and b receptor autophosphorylation at concentrations up to 10 mM (Kovalenko et al., 1994) . Above this concentration, speci®city is lost and other signaling pathways begin to become impaired. AG1296 has been utilized in many systems to analyse the role PDGFR plays in a variety of cellular phenotypes (Krystal et al., 1997; Rice et al., 1999) . The EFT cell line TC71 used in this assay has been previously shown to express high levels of PDGF-C (Zwerner and May, 2001 ). TC71 cells were plated in soft agar in conditions under which colonies form within 2 ± 3 weeks incubation. Such anchorage-independent growth is one characteristic of a transformed cellular phenotype. Increasing concentrations of AG1296 were utilized. Soft agar foci formation can be clearly inhibited at AG1296 concentrations as low as 2.5 mM (Figure 1 ), signi®cantly less than the maximal selective concentration of 10 mM. These ®ndings were consistent across three independent experiments. These data support the hypothesis that PDGFR signaling is important to the anchorageindependent growth of at least one EFT cell line. Given its known receptor anities, these data suggest that PDGF-C may be involved as the ligand in this autocrine loop.
PDGF-C-HA3 acts in a dominant-negative fashion to decrease PDGF-C signaling Although AG1296 shows speci®city for the PDGFR, it could easily be aecting other growth factor pathways. In particular, AG1296 has also been shown to inhibit the related c-Kit receptor tyrosine kinase (Kovalenko et al., 1994) . c-Kit and its ligand, stem cell factor (SCF), are expressed within several EFT cell lines. Additionally, blockage of c-Kit/SCF signaling within several of these cell lines led to decreased cellular proliferation and increased apoptosis (Ricotti et al., 1998) . Therefore, it is possible that the ability of AG1296 to inhibit TC71 anchorage-independent growth is due to its disruption of the c-Kit/SCF, not the PDGF-C/PDGFR, autocrine loop.
In order to determine between these possibilities, we set out to design a more speci®c inhibitor of PDGF-C signaling. Several methods have been employed to inhibit ligand/receptor interactions at the cell surface including the use of antibodies and soluble receptor molecules (Duan et al., 1991; Vassbotn et al., 1990) . However, PDGF-B has been shown to transform cells via an internal activation mechanism, which is insensitive to such extracellular approaches (Bejcek et al., 1989) . Destabilized conserved cystine mutants of PDGF-A have been shown to form heterodimers with PDGF-B and block this intracellular PDGF-B signaling in astrocytoma cell lines (Mercola et al., 1990; Shamah et al., 1993) . Due to the structural similarity between PDGF-A and PDGF-C, we adopted a similar approach to create a PDGF-C dominant negative construct. Using a C-terminal triple hemagglutinin tag (HA3) for protein detection, we found that our unstable mutant proteins failed to block transformation by wild-type PDGF-C, while stable mutants did inhibit PDGF-C transformation. We subsequently determined that this inhibition was conferred by the simple addition of the C-terminal triple HA to wildtype PDGF-C. The inhibitory activity of triple HA tagged (PDGF-C-HA3) is shown in Figure 2 . NIH3T3 cells transduced with empty vector control or wild-type PDGF-C were also transduced with retrovirus expressing the dominant negative PDGF-C-HA3. PDGF-C-HA3 eectively blocks PDGF-C transformation in this system. These results demonstrate that the PDGF-C-HA3 acts as a dominant inhibitor of wild-type PDGF-C transformation. Additionally, these results suggest that PDGF-C-HA3 acts via a dierent mechanism than that utilized by previously described PDGF dominant negative mutants.
Dominant negative PDGF-C-HA3 is stable and dimerizes with wild-type
PDGF-C biologic activity is dependant upon appropriate processing of the protein via secretion, dimerization, and activation by proteolytic cleavage. To better understand the mechanism by which PDGF-C-HA3 is able to inhibit PDGF-C transformation, we ®rst evaluated whether the inhibitory HA3 moiety interferes with any of these steps. We co-expressed PDGF-C-HA3 in NIH3T3 cells already expressing either empty vector or a PDGF-C construct tagged with a single Cterminal FLAG epitope. This FLAG tagged PDGF-C demonstrates transformation activity identical to wildtype PDGF-C (data not shown), con®rming that it is approximately processed with adequate protein levels. Supernatants from these cell lines were collected, concentrated, and immunoprecipitated with anti-FLAG antisera. The immunoprecipitated protein was then electrophoresed under reducing conditions and blotted to nitrocellulose. As shown in Figure 3 , PDGF-C-HA3 is detectable both in the a-HA and in the a-FLAG immunoprecipitates. The size of the HA3 protein detected is consistent with fully processed PDGF-C which has undergone proteolytic cleavage of the large inhibitory N-terminal CUB domain. These data indicate that the HA3 epitope does not impair PDGF-C stability, secretion or extracellular processing, all of which are required for full biological activity. The presence of HA3 protein in the a-FLAG IP also demonstrates that PDGF-C-HA3 dimerizes with a biologically active form of PDGF-C. Such dimerization is a further requirement for PDGF-C receptor binding and activity. Since the triple HA tag has disturbed none of these antecedent steps in PDGF-C processing, we postulated that the inhibition observed with PDGF-C-HA3 results from a decreased ability of these mutant/wild-type heterodimers to stimulate PDGF receptor.
Dominant negative PDGF-C-HA3 is an attenuated PDGFR agonist that inhibits native PDGF-C signaling
As mentioned previously, PDGF-C has been shown to primarily bind and activate PDGFR-a. In the presence of PDGFR-a, PDGF-C may also bind and activate PDGFR-b (Gilbertson et al., 2001) , but it will not bind PDGFR-b alone. If the HA3 mutant of PDGF-C works as we postulate, it should primarily decrease PDGFR-a activation. To test this hypothesis, we employed supernatant media from NIH3T3 cells expressing high levels of PDGF-C-FLAG alone, PDGF-C-HA3 alone, or both of these PDGF-C species. NIH3T3 cells transduced with empty vector alone were included as a negative control. After 2 days incubation in serum free media, supernatant media from each of these lines was collected, ®ltered, and
Figure 2 Dominant negative PDGF-C inhibits PDGF-C transformation of NIH3T3 cells. Polyclonal populations of both NIH3T3 and of NIH3T3 expressing retroviral wild-type PDGF-C were superinfected with either dominant negative PDGF-C-HA3 retrovirus or with a GFP retroviral control. These populations underwent selection with another antibiotic and were plated in soft agar. Co-expression of dominant negative PDGF-C-HA3 clearly inhibits transformation by wild-type PDGF-C Figure 3 Dominant negative PDGF-C dimerizes with wild-type PDGF-C from cell supernatants. Concentrated supernatant from cells co-expressing both FLAG tagged wild-type PDGF-C along with dominant negative PDGF-C-HA3 were immunoprecipitated with either a-HA antisera or a-FLAG antisera. IP product was electrophoresed, Western blotted, and probed with a-HA antisera. The FLAG IP contained PDGF-C-HA3 indicating this dominant negative protein is stable, appropriately secreted and dimerizes with wild-type. Supernatants from cells expressing only PDGF-C-HA3 or PDGF-C-FLAG are included as positive and negative controls then used to stimulate unmanipulated, serum-starved NIH3T3 cells. Lysates of these stimulated cells were immunoprecipitated with anti-PDGFR-a, electrophoresed under reducing conditions and blotted to nitrocellulose. The phosphorylation status of the proteins was then accessed by probing the blots with an antibody speci®c for phosphorylated tyrosine residues. As can be seen in Figure 4a , in contrast to the activation seen with PDGF-C-FLAG, PDGF-C-HA3 supernatants are unable to activate PDGFR-a above background levels. Since we have shown that PDGF-C-HA3 is correctly secreted and processed, this result clearly supports a model in which the triple HA epitope inhibits receptor activation by either primarily decreasing PDGFR binding or by inhibiting the ability of bound ligand to induce receptor dimerization and subsequent activation. Supernatants from those cells co-expressing both PDGF-C-FLAG and PDGF-C-HA3 also fail to activate PDGFR-a. Therefore, the ability of PDGF-C-HA3 to abrogate PDGF-C induced anchorage-independent growth appears to stem from its inhibition of PDGF-C signaling at the cell surface.
To further de®ne the ability of PDGF-C-HA3 to act as a speci®c inhibitor of cellular transformation, we next accessed the ability of PDGF-C-HA3 to inhibit signaling pathways downstream of PDGF-C/PDGFR that are known to be vital for anchorage-independent growth. Activation of the Ras/Raf/MEK/MAP kinase pathway is one of the many consequences of PDGFR autophosphorylation (Nanberg and Westermark, 1993) . MEK1 activation, which subsequently activates the MAP kinase family members ERK1 and ERK2, has been shown to be necessary and sucient for NIH3T3 transformation as accessed by colony formation in soft agar (Cowley et al., 1994 ). This suggests that the level of activated ERK1/2 may indicate the transformed status of the cell. This increase in ERK phosphorylation has also recently been shown to be vital for NIH3T3 cell transformation by EWS/FLI (Silvany et al., 2000) . To measure whether downstream ERK phosphorylation is aected by PDGF-C-HA3, supernatants from the cells detailed above were again used to stimulate serum-starved NIH3T3 target cells ( Figure 4b ). As expected, supernatants from cells expressing PDGF-C-FLAG resulted in a marked increase in ERK1/2 phosphorylation in target cells when compared with baseline NIH3T3 cell extracts. In comparison, the level of ERK1/2 activation was dramatically reduced when supernatants from cells co-expressing PDGF-C-FLAG and PDGF-C-HA3 were used. Although PDGF-C-HA3 alone still activates ERK1/2 above baseline in both NIH3T3 and in EWS/FLI expressing NIH3T3, this activation was only a fraction of that seen with wild-type PDGF-C. Activation by these supernatants is speci®c to PDGF signaling in that it is ablated by selective concentrations of AG1296 (data not shown).
Taken together, these results suggest that the PDGF-C-HA3 construct produces stable protein that, despite dramatically reduced biological activity, is still able dimerize with biologically active PDGF-C. The mechanism of PDGF-C-HA3 action most consistent with these results is that PDGF-C-HA3 is able to sequester endogenous PDGF-C in a heterodimer that is a b Figure 4 Dominant negative PDGF-C is a weakened agonist that inhibits wild-type PDGF-C signaling. In both panels, cells stably expressing the construct of interest were grown in serumfree media for 2 days. After this incubation, the conditioned media was collected, ®ltered, and applied to serum-starved, unmanipulated NIH3T3 cells. The stimulated cells were then processed as described. (a) Dominant negative PDGF-C inhibits wild-type PDGF-C signaling at the cell surface. Lysates from NIH3T3 cells stimulated with various conditioned media were immunoprecipitated with an anti-PDGFR-a antibody. The resulting immunoprecipitated proteins were blotted to nitrocellulose and probed with an antibody speci®c to phosphorylated tyrosine residues. As can be seen, in contrast to PDGF-C-FLAG, PDGF-C-HA3 does not activate the receptor above background levels. When coexpressed, PDGF-C-HA3 is able to inhibit the ability of PDGF-C-FLAG to stimulate PDGFR-a. The blots were then stripped and probed with an anti-PDGFR-a antibody to control for loading. (b) Dominant negative PDGF-C inhibits a PDGF-C signal transduction pathway relevant to cellular transformation. Lysates of stimulated cells were blotted to nitrocellulose and probed with an anti-phosphorylated ERK1/2 antibody. PDGF-C-HA3 is able to induce ERK1/2 activation above background levels, albeit to a much lower degree than PDGF-C-FLAG. When PDGF-C-HA3 is coexpressed with PDGF-C-FLAG there is a dramatic decrease in ERK1/2 stimulation, suggesting that the dominant negative protein is able to inhibit PDGF-C signal transduction. The blots were stripped and probed with an anti-total ERK1 and ERK2 antibody to control for loading unable to eectively activate PDGFR and induce downstream events such as ERK1/2 phosphorylation. Additionally, PDGF-C-HA3 homodimers may bind receptor without inducing receptor dimerization/autophosphorylation and render these receptors inaccessible to wild-type PDGF-C. Regardless of which mechanism is most important, the end result is the same: speci®c inhibition of wild-type PDGF-C signaling and its induction of anchorage-independent growth.
Expression of PDGF-C-HA3 within EFT tumor cell lines inhibits anchorage-independent growth and tumorigenesis
In order to determine the role of PDGF-C in EFT tumor cell lines, we went on to measure the eect of dominant negative blockade in this cellular context. We used recombinant retroviral vectors to introduce PDGF-C-HA3 into three EFT cell lines known to express high levels of PDGF-C (Zwerner and May, 2001 ). These lines included TC71, a type 1 EWS/FLI Ewing's line, TC32, a type 1 EWS/FLI pPNET, and TTC466, and EWS/ERG expressing Ewing's line. Control lines were transduced with a vector expressing the GFP protein. Pure polyclonal populations were derived by antibiotic selection. These polyclonal cell lines were plated in soft agar under conditions in which the unmanipulated lines form colonies in 14 ± 21 days ( Figure 5) . In all three cell lines, the number and size of colonies formed was signi®cantly reduced compared to the controls. These results were consistent across three independent experiments. These results indicate that speci®c blockade of PDGF-C signaling is sucient to attenuate anchorage-independent growth in these EFT cell lines. This ®nding suggests that PDGF-C may play a similar role in primary EFT expressing PDGF-C.
Discussion
Growth factors have long been implicated in the process of cellular transformation (Aaronson, 1991) . Somatic cells are obligatorily dependent upon their environment for continuous provision of trophic factors. Transformed cells may bypass this reliance by aberrantly expressing both a ligand and its responsive receptor. These autocrine loops allow for constitutive cellular proliferation, one of the hallmarks of oncogenesis (Hanahan and Weinberg, 2000) . Such unchecked mitogenic signaling also allows the malignant cell to thrive even when area resources begin to limit the size of the tumor, as well as within foreign environments where the typical complement of growth factors are not present. The importance of growth factor signaling is evidenced by the clinical success of several therapeutic approaches that have been utilized to disrupt these autocrine loops (Kumar et al., 2000) .
Several independent observations suggest that growth factor signaling may play an important role in EWS/FLI-induced malignancies. First, treatment of EFT tumor cell lines with suramin, a non-speci®c growth factor inhibitor, leads to the reversion of their malignant phenotype (Scotlandi et al., 1998) . This ®nding was originally taken to show the importance of another growth factor, IGF-1, to the malignant phenotype in EFT cell lines, but can apply to other growth factors as well. Second, the Ras/Raf-1/MEK/ ERK1-2 pathway has recently been shown to be constitutively active within both NIH3T3 cells overexpressing EWS/FLI as well as in several EFT tumor cell lines (Silvany et al., 2000) . This pathway is commonly used by transmembrane receptors to convey extracellular information into the nucleus and ultimately to produce a diverse array of biological responses (Schaeer and Weber, 1999) . Additionally, blockage of ERK1 and ERK2 activation within NIH3T3 cells expressing EWS/FLI prevents soft agar colony formation (Silvany et al., 2000) . Finally, mutations that result in constitutively active Ras, which occur in roughly 25% of all human malignancies, are very rare in EFT (Radig et al., 1998 ). An explanation suggested by this rarity is that EWS/ets chimera mediate an event either upstream or independent of Ras which accounts for the constitutive ERK1/ 2 activation observed in EFT.
Recent data from our lab had suggested that PDGF-C might be responsible for this EWS/FLI-induced growth factor signaling (Zwerner and May, 2001) . EWS/FLI induces PDGF-C expression when overexpressed in NIH3T3 cells. PDGF-C, which acts as a potent oncogenic stimulus within NIH3T3 cells, is also expressed in several EFT cell lines and patient specimens. Furthermore, the ability of EWS/FLI to transform NIH3T3 cells is dependent upon PDGFR signaling (Zwerner and May, submitted) . In this study we extend these ®ndings into a more relevant system. First, AG1296, a speci®c PDGFR inhibitor, was shown to abrogate anchorage-independent growth in an EFT cell line known to express high levels of PDGF-C. This demonstrates that, at least for this cell line, autocrine signaling pathways involving PDGFR play an important role in the EWS/ets malignant phenotype. Second, we were also able to block anchorageindependent growth in several EFT cell lines by Figure 5 Dominant negative PDGF-C inhibits growth of EFT cell lines. Three EFT cell lines were infected with either PDGF-C-HA3 dominant negative retrovirus or a GFP retrovirus control and polyclonal populations were selected with antibiotics. These cell populations were plated in soft agar. PDGF-C-HA3 dominant negative clearly inhibits anchorage-independent growth of all three lines expression of a dominant negative PDGF-C construct. When taken with the ®nding that PDGF-C binds to and signals through PDGFR (Gilbertson et al., 2001) , these data strongly implicate PDGF-C as an EWS/ets downstream target that is important to the EFT malignant phenotype.
Given its familial association, it is not surprising that PDGF-C would be implicated in human malignancy. Upon activation, PDGFR signaling leads to several outcomes that are hallmarks of the malignant phenotype including proliferation, protection from apoptosis, and chemotaxis (metastasis) . The resulting phenotype is dependent upon the complement of receptor homo-or heterodimers created, as each is able to activate dierent signal transduction pathways. The ®nding that PDGF-C seems to act much like the PDGF-AB heterodimer, the most mitogenic of all the PDGF subtypes, only further supports its role as an oncogene (Ekman et al., 1999; Gilbertson et al., 2001) . One of the earliest indications that unregulated PDGF/PDGFR signaling can lead to cellular transformation came with the discovery that PDGF-B is identical to the v-sis oncogene (Doolittle et al., 1983) . Subsequently autocrine loops involving PDGF/PDGFR have been linked to several human malignancies including osteosarcoma, lung carcinoma, glioma and malignant astrocytoma (Antoniades et al., 1992; Guha et al., 1995; Hermanson et al., 1992; Sulzbacher et al., 2000) . In the case of astrocytoma, the requirement for a PDGF/PDGFR autocrine loop was also demonstrated by a dominantnegative form of the ligand which was able to revert the transformed phenotype of these cells (Shamah et al., 1993) . In line with PDGF/PDGFR's broad range of involvement in malignancy, PDGF-C expression has been demonstrated in cell lines from several human tumors including sarcomas, carcinomas and leukemias (Uutela et al., 2001) . In addition to its role in autocrine signaling, PDGF has also been shown to exacerbate tumor growth by stimulating the proliferation of stromal tissue and vasculature (Nakayama et al., 1998; Sundberg et al., 1997; Vignaud et al., 1994) . Expression data, as well as its ability to stimulate extensive vascularization in a wound repair model, suggest that PDGF-C may participate in similar paracrine interactions in route to its induction of malignancy (Uutela et al., 2001) .
The results obtained in this study suggest that PDGF-C may serve as a viable therapeutic target in the treatment of EFT. The tyrosine kinase inhibitor STI571 shows promise in this regard (Druker et al., 2001) . Originally developed to block signaling of the bcr ± abl translocation product, this drug has subsequently been shown to block PDGFR as well (Buchdunger et al., 2000) . STI571 has already been shown to increase apoptosis and reduce tumor growth in cell lines derived from dermato®brosarcoma protuberans, a tumor that is dependent upon PDGFR autocrine signaling (Sjoblom et al., 2001) . We are currently evaluating this compound for its ability to inhibit EFT cell line tumor formation.
Materials and methods
Cells and cell culture
All cell lines were grown in 5% CO 2 , and all medium was supplemented with 1 mM glutamine (Q) and penicillin/ streptomycin. EFT cell lines were grown in DMEM+20% fetal calf serum (FCS). NIH3T3 cells and all cell lines derived from them were grown in DMEM+5% bovine calf serum (CS). The development of NIH3T3 cells expressing either EWS/FLI or murine PDGF-C have been described elsewhere. For serum starvation experiments, cells were grown for 48 h in DMEM+0.5% bovine serum albumin (BSA) to induce quiescence. After 48 h, the media was replaced and the cells were allowed to incubate for 2 h prior to stimulation. For stimulation experiments, cells expressing the appropriate construct(s) were plated in 6-well plates at a concentration such that they would reach con¯uency 2 days post plating. These cells were grown in DMEM+0.5% BSA. After 48 h, the supernatants from each con¯uent plate were collected and passed through a 0.45 mM ®lter. One milliliter of this ®ltered, conditioned media was then used to simulate serum-starved cells. After a 15-min incubation, the stimulated cells were lysed and subjected to either immunoprecipitation followed by immunoblot or immunoblot alone depending upon the experiment.
Creation of PDGF-C dominant negative
The Quickchange mutagenesis kit (Stratagene) was used to mutate the cystine residues of the PDGF-C cystine knot region to serines (primer sequences available upon request). The template for these reactions was a full-length, unmutated clone of murine PDGF-C subcloned into pNEB193 (New England Biolabs, USA). After following the Quickchange manufacturer's protocol, the resulting mutants were cloned into the HindIII/PmeI sites of pCDNA3.1 ± HA3 (kindly provided by Evans Baily). This vector adds three hemagglutinin (HA) epitope tags to the carboxy terminus of the mature protein. Each HA-tagged mutant was then subcloned into the HindIII/BamHI site of the retroviral expression vector MaRXIVrZeo. To create a human dominant negative construct, full-length, unmutated human PDGF-C was subcloned into the HindIII/PmeI sites of pCDNA3.1 ± HA3. The insert, now tagged with the triple-HA epitope, was then subcloned into the HindIII/BamHI sites of MaRXIVrZeo.
Transfections and selection
All plasmid DNA used for transfection was puri®ed via ion exchange chromatography (Qiagen, Chatsworth, CA, USA). DNA was introduced into the LinxA amphotropic cell line using a previously described Ca 2 PO 4 procedure. Two days post transfection, viral stocks were collected and used to infect either NIH3T3 cells or EFT cell lines. The transduced cells were then selected for zeocin resistance: NIH3T3 cells at 50 mg of zeocin/ml of media and EFT cell lines at 25 mg of zeocin/ml of media.
Antibodies, immunoblotting and immunoprecipitation
Primary antibodies The anti-phospho-ERK1/2, anti-p-Tyr (PY99), and anti-PDGFR-a antibodies were obtained from Santa Cruz Biotechnologies (Santa Cruz, CA, USA). The anti-total-ERK1/2 antibody was acquired from Cell Signaling Technologies (Beverly, MA, USA), the anti-FLAG M2 antibody was obtained from Kodak and the anti-HA monoclonal antibody was purchased from Covance (Princeton, NJ, USA).
Secondary antibodies Both the anti-mouse and the antirabbit IgG ± HRP antibodies were purchased from Jackson Labs (West Grove, PA, USA). To perform immunoblotting to access ERK1/2 phosphorylation status, cells were ®rst grown on 6-well plates. Upon reaching con¯uence, cells were lysed in SDS sample buer. Lysates were then subjected to a few seconds of sonication and boiled for 5 min. After boiling, proteins were separated by SDS ± PAGE and transferred to a nitrocellulose membrane with a semi-dry transblotting device (Bio-rad). Membranes were then subjected to 1 h of blocking with 5% nonfat milk in TBS (25 mM Tris, 150 mM NaCl, 3 mM KCl, pH 8.0), followed by incubation with an appropriate primary antibody diluted in TBS/5% nonfat milk. After 1 h incubation with the primary antibody the membrane was washed four times with TTBS (TBS+0.05% Tween 20) and then incubated with a dilution of the appropriate horseradish-peroxidase-linked secondary antibody in TBS/5% nonfat milk. After 45 min incubation, the membrane was washed four times with TTBS and then developed with the Pierce SuperSignal Chemiluminescent Substrate (Rockford, IL, USA) per the manufacturer's instructions. Chemiluminescence was detected at several time points with Kodak ®lm. To strip the blots before re-probing with another primary antibody, the membranes were incubated in Restore TM Western blot stripping buer (Pierce, Rockford, IL, USA) per manufacturer's instructions. To access the phosphorylation status of PDGFR-a, cells stimulated with conditioned media were lysed in RIPA buer containing protease (complete mini tablet, Roche, Indianapolis, IN, USA) and phosphatase (1 mM Na 3 VO 4 , 1 mM NaF) inhibitors. After 20 min the lysates were centrifuged at 12 000 g for 10 min to remove cellular debris. The supernatants were then incubated with 2 mg of anti-PDGFR-a antibody for 2 h on ice. Following the incubation, the lysates were immunoprecipitated/immunoblotted as described elsewhere in this manuscript.
Co-immunoprecipitation of epitope tagged PDGF-C NIH3T3 cells stably expressing both HA-and FLAG-tagged PDGF-C were grown to con¯uency. Conditioned media from these cells was collected and concentrated in a micron column (10 kDa MWCO). The concentrate was diluted in PBS containing a cocktail of protease inhibitors (mini complete protease table, Roche) and then incubated for 1 h with 2 mg of anti-FLAG M2 antibody. After the incubation, 50 ml of protein A-sepharose/PBS (1 : 1) was added and incubated for another hour. The sample was then centrifuged at 1000 g for 3 min and the supernatant discarded. The sepharose pellet was washed four times in 250 ml of PBS containing protease inhibitors, centrifuging as above after each wash. After the ®nal wash the pellet was resuspended in 40 ml SDS sample buer and boiled for 5 min. The denatured supernatant was then separated by SDS ± PAGE and analysed by immunoblotting with the anti-HA monoclonal serving as the primary antibody.
Soft agar transformation assay
Polyclonal, selected populations of the cell type to be analysed were plated in soft agar in a 6-well plate. NIH3T3 cells were plated at both 2000 and 10 000 cells/well; EFT cell lines were plated at 20 000 cells/well. The agar was made with Iscove's medium as described previously (May et al., 1993a) . In experiments involving NIH3T3 cells, the soft agar was supplemented with 10% CS. EFT cell lines required higher concentrations of serum: TC71 cells were grown in 20% FCS, TC32 and TTC446 cells were grown in 30% FCS. In addition, other appropriate reagents were added as required for each individual experiment.
